 Margaret Wierman
Concepts (636)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonadotropin-Releasing Hormone | 40 | 2020 | 188 | 5.470 |
Why?
| | Androgens | 17 | 2022 | 167 | 5.380 |
Why?
| | Testosterone | 23 | 2023 | 343 | 5.210 |
Why?
| | Pituitary Neoplasms | 11 | 2018 | 157 | 2.770 |
Why?
| | Neurons | 22 | 2020 | 1279 | 2.560 |
Why?
| | Gonadal Steroid Hormones | 9 | 2020 | 124 | 2.490 |
Why?
| | Endocrinology | 7 | 2016 | 70 | 2.360 |
Why?
| | Receptor Protein-Tyrosine Kinases | 9 | 2014 | 226 | 2.230 |
Why?
| | Adrenocortical Carcinoma | 8 | 2023 | 47 | 2.230 |
Why?
| | Adenoma | 9 | 2018 | 189 | 2.140 |
Why?
| | Sexual Dysfunction, Physiological | 6 | 2019 | 60 | 2.020 |
Why?
| | Pituitary Gland | 10 | 2018 | 148 | 1.840 |
Why?
| | Adrenal Cortex Neoplasms | 7 | 2023 | 48 | 1.670 |
Why?
| | Hormone Replacement Therapy | 4 | 2022 | 77 | 1.560 |
Why?
| | Periodicals as Topic | 5 | 2016 | 181 | 1.460 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.440 |
Why?
| | Sexual Dysfunctions, Psychological | 3 | 2019 | 31 | 1.400 |
Why?
| | Cell Movement | 12 | 2015 | 868 | 1.390 |
Why?
| | Proto-Oncogene Proteins | 10 | 2018 | 608 | 1.350 |
Why?
| | Reproduction | 5 | 2011 | 178 | 1.340 |
Why?
| | Oncogene Proteins | 6 | 2008 | 53 | 1.310 |
Why?
| | Follicle Stimulating Hormone | 16 | 2023 | 216 | 1.270 |
Why?
| | Luteinizing Hormone | 15 | 2023 | 169 | 1.240 |
Why?
| | Postmenopause | 8 | 2019 | 303 | 1.230 |
Why?
| | Estradiol | 14 | 2019 | 455 | 1.230 |
Why?
| | Hyperandrogenism | 2 | 2021 | 14 | 1.110 |
Why?
| | Dehydroepiandrosterone | 6 | 2022 | 49 | 1.060 |
Why?
| | Hypogonadism | 6 | 2014 | 75 | 1.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 7 | 2014 | 351 | 1.010 |
Why?
| | Adrenal Cortex | 4 | 2020 | 32 | 1.000 |
Why?
| | Publishing | 3 | 2015 | 124 | 0.980 |
Why?
| | Gene Expression Regulation | 14 | 2015 | 2319 | 0.910 |
Why?
| | Ovary | 7 | 2018 | 191 | 0.860 |
Why?
| | Promoter Regions, Genetic | 12 | 2012 | 1131 | 0.850 |
Why?
| | Consensus | 3 | 2020 | 537 | 0.850 |
Why?
| | Gonadotrophs | 6 | 2015 | 21 | 0.850 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2023 | 1141 | 0.840 |
Why?
| | Hypothalamus | 9 | 2011 | 147 | 0.790 |
Why?
| | Humans | 110 | 2023 | 114654 | 0.790 |
Why?
| | Societies, Medical | 6 | 2019 | 663 | 0.780 |
Why?
| | Neurosurgical Procedures | 4 | 2020 | 152 | 0.760 |
Why?
| | Cell Proliferation | 12 | 2023 | 2186 | 0.750 |
Why?
| | Anovulation | 1 | 2021 | 8 | 0.750 |
Why?
| | Bicycling | 1 | 2021 | 86 | 0.730 |
Why?
| | Animals | 57 | 2023 | 31698 | 0.710 |
Why?
| | Genes, Tumor Suppressor | 3 | 2017 | 77 | 0.710 |
Why?
| | Polycystic Ovary Syndrome | 2 | 2021 | 141 | 0.700 |
Why?
| | Eunuchism | 1 | 2020 | 3 | 0.690 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 1394 | 0.670 |
Why?
| | Estrogens | 7 | 2022 | 312 | 0.670 |
Why?
| | Acromegaly | 2 | 2020 | 12 | 0.650 |
Why?
| | Sexual Maturation | 4 | 2014 | 47 | 0.640 |
Why?
| | Female | 63 | 2022 | 59488 | 0.630 |
Why?
| | Cell Survival | 8 | 2021 | 1020 | 0.620 |
Why?
| | Cell Line | 17 | 2015 | 2635 | 0.620 |
Why?
| | Hypopituitarism | 3 | 2014 | 15 | 0.620 |
Why?
| | Mice | 26 | 2020 | 14863 | 0.600 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 30 | 0.580 |
Why?
| | Andropause | 2 | 2014 | 6 | 0.570 |
Why?
| | Desmosomes | 1 | 2017 | 20 | 0.570 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 13 | 0.520 |
Why?
| | Adipocytes | 1 | 2017 | 188 | 0.510 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.510 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 2710 | 0.510 |
Why?
| | Repressor Proteins | 2 | 2015 | 366 | 0.510 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 69 | 0.500 |
Why?
| | Antibodies | 1 | 2017 | 371 | 0.490 |
Why?
| | Erectile Dysfunction | 4 | 1999 | 38 | 0.490 |
Why?
| | Premenopause | 4 | 2019 | 106 | 0.490 |
Why?
| | Signal Transduction | 13 | 2019 | 4512 | 0.490 |
Why?
| | Protein Kinase Inhibitors | 3 | 2015 | 785 | 0.480 |
Why?
| | Brain Injuries, Traumatic | 1 | 2020 | 301 | 0.480 |
Why?
| | Serial Publications | 1 | 2014 | 2 | 0.480 |
Why?
| | Membrane Proteins | 2 | 2019 | 1018 | 0.480 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2014 | 18 | 0.480 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 164 | 0.470 |
Why?
| | Human Growth Hormone | 1 | 2014 | 38 | 0.460 |
Why?
| | Cadherins | 1 | 2015 | 175 | 0.460 |
Why?
| | Biological Assay | 1 | 2014 | 112 | 0.460 |
Why?
| | Editorial Policies | 1 | 2014 | 45 | 0.450 |
Why?
| | Histone Deacetylases | 1 | 2015 | 195 | 0.430 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2015 | 398 | 0.430 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2013 | 14 | 0.430 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 551 | 0.420 |
Why?
| | Middle Aged | 29 | 2023 | 26732 | 0.420 |
Why?
| | Antineoplastic Agents | 4 | 2019 | 1879 | 0.420 |
Why?
| | Veterans | 2 | 2023 | 1249 | 0.420 |
Why?
| | Endocrine Glands | 2 | 2010 | 15 | 0.420 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2013 | 67 | 0.410 |
Why?
| | Vagina | 1 | 2014 | 146 | 0.410 |
Why?
| | Tumor Suppressor Proteins | 4 | 2011 | 282 | 0.410 |
Why?
| | Estrogens, Conjugated (USP) | 2 | 2015 | 34 | 0.410 |
Why?
| | Dihydrotestosterone | 3 | 2010 | 39 | 0.400 |
Why?
| | Apoptosis | 9 | 2021 | 2362 | 0.390 |
Why?
| | Women's Health | 2 | 2019 | 271 | 0.390 |
Why?
| | Bone Density | 4 | 2020 | 432 | 0.380 |
Why?
| | Male | 45 | 2023 | 55579 | 0.380 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.380 |
Why?
| | Pituitary Apoplexy | 1 | 2011 | 1 | 0.380 |
Why?
| | Estrous Cycle | 1 | 2011 | 14 | 0.380 |
Why?
| | Immunohistochemistry | 7 | 2018 | 1629 | 0.370 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 146 | 0.370 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 164 | 0.370 |
Why?
| | Models, Molecular | 1 | 2015 | 1369 | 0.370 |
Why?
| | Estrone | 1 | 2010 | 35 | 0.360 |
Why?
| | Evidence-Based Medicine | 3 | 2014 | 668 | 0.360 |
Why?
| | Adult | 26 | 2023 | 30542 | 0.350 |
Why?
| | Glycoproteins | 1 | 2012 | 304 | 0.350 |
Why?
| | Myocardial Infarction | 2 | 2014 | 927 | 0.350 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1996 | 153 | 0.350 |
Why?
| | Menstrual Cycle | 1 | 2010 | 108 | 0.340 |
Why?
| | Brain Injuries | 3 | 2014 | 461 | 0.330 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 849 | 0.330 |
Why?
| | RNA, Messenger | 14 | 2011 | 2552 | 0.330 |
Why?
| | Transcription, Genetic | 5 | 2002 | 1313 | 0.320 |
Why?
| | Diagnosis, Differential | 5 | 2021 | 1342 | 0.320 |
Why?
| | Trans-Activators | 2 | 2021 | 367 | 0.320 |
Why?
| | MAP Kinase Signaling System | 2 | 2018 | 276 | 0.310 |
Why?
| | Kallmann Syndrome | 3 | 2020 | 8 | 0.310 |
Why?
| | Stroke | 2 | 2014 | 1021 | 0.310 |
Why?
| | Aged | 18 | 2023 | 19068 | 0.310 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1040 | 0.290 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 180 | 0.290 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2015 | 740 | 0.290 |
Why?
| | Medroxyprogesterone | 1 | 2007 | 10 | 0.290 |
Why?
| | Liver Neoplasms | 2 | 2023 | 506 | 0.280 |
Why?
| | Hirsutism | 2 | 2021 | 10 | 0.280 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2007 | 16 | 0.280 |
Why?
| | Global Health | 2 | 2019 | 287 | 0.280 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 430 | 0.280 |
Why?
| | Rats | 21 | 2018 | 4958 | 0.280 |
Why?
| | Infertility | 1 | 2007 | 45 | 0.280 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 32 | 0.280 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 4692 | 0.270 |
Why?
| | Proteins | 3 | 2003 | 908 | 0.270 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 1879 | 0.270 |
Why?
| | Neurogenesis | 3 | 2013 | 102 | 0.270 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 386 | 0.260 |
Why?
| | Cell Nucleus | 2 | 2015 | 554 | 0.260 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 260 | 0.260 |
Why?
| | Mice, Knockout | 4 | 2014 | 2568 | 0.260 |
Why?
| | Base Sequence | 11 | 2008 | 2114 | 0.250 |
Why?
| | Prolactinoma | 2 | 2018 | 11 | 0.250 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 313 | 0.250 |
Why?
| | Blood Coagulation | 1 | 2007 | 218 | 0.250 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 329 | 0.240 |
Why?
| | Transfection | 6 | 2015 | 866 | 0.240 |
Why?
| | Protein Binding | 4 | 2015 | 1889 | 0.240 |
Why?
| | Vasodilation | 1 | 2007 | 419 | 0.230 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 1727 | 0.230 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2002 | 278 | 0.220 |
Why?
| | Up-Regulation | 4 | 2021 | 807 | 0.220 |
Why?
| | DNA | 9 | 2012 | 1352 | 0.220 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 27 | 0.220 |
Why?
| | Models, Biological | 4 | 2012 | 1620 | 0.220 |
Why?
| | Femur Neck | 2 | 2020 | 59 | 0.210 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2019 | 113 | 0.210 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 529 | 0.210 |
Why?
| | Cytoplasm | 2 | 2015 | 255 | 0.210 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 146 | 0.210 |
Why?
| | Double-Blind Method | 4 | 2020 | 1660 | 0.210 |
Why?
| | Anorexia | 1 | 2022 | 18 | 0.200 |
Why?
| | Disease Models, Animal | 3 | 2020 | 3531 | 0.200 |
Why?
| | Body Composition | 4 | 2018 | 590 | 0.200 |
Why?
| | Stress, Physiological | 2 | 2015 | 378 | 0.200 |
Why?
| | RNA, Small Interfering | 3 | 2019 | 535 | 0.190 |
Why?
| | Aldosterone | 2 | 2019 | 42 | 0.190 |
Why?
| | Cytoskeletal Proteins | 1 | 2002 | 145 | 0.190 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 48 | 0.190 |
Why?
| | Heat-Shock Proteins | 1 | 2002 | 113 | 0.190 |
Why?
| | Transcription Factors | 2 | 2000 | 1528 | 0.190 |
Why?
| | DNA-Binding Proteins | 2 | 2014 | 1314 | 0.190 |
Why?
| | Puberty, Precocious | 5 | 1992 | 13 | 0.190 |
Why?
| | Aurora Kinase A | 1 | 2021 | 51 | 0.180 |
Why?
| | Myogenic Regulatory Factors | 1 | 2000 | 49 | 0.180 |
Why?
| | Receptors, Androgen | 1 | 2002 | 131 | 0.180 |
Why?
| | Receptors, Somatotropin | 1 | 2020 | 9 | 0.180 |
Why?
| | Phthalazines | 1 | 2021 | 38 | 0.180 |
Why?
| | Somatostatin | 1 | 2020 | 52 | 0.180 |
Why?
| | Dopamine Agonists | 1 | 2020 | 32 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2021 | 54 | 0.180 |
Why?
| | Paraganglioma | 1 | 2021 | 47 | 0.180 |
Why?
| | Adrenal Gland Diseases | 1 | 2020 | 6 | 0.180 |
Why?
| | Benzamides | 1 | 2021 | 169 | 0.180 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 921 | 0.180 |
Why?
| | Immunoblotting | 2 | 2018 | 283 | 0.180 |
Why?
| | Neoplasm Invasiveness | 3 | 2012 | 442 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 85 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 497 | 0.170 |
Why?
| | Young Adult | 6 | 2020 | 10465 | 0.170 |
Why?
| | Receptors, Progesterone | 3 | 2003 | 319 | 0.170 |
Why?
| | Radiotherapy | 1 | 2020 | 176 | 0.170 |
Why?
| | Hospital Medicine | 1 | 2021 | 82 | 0.170 |
Why?
| | Pyrazoles | 2 | 2013 | 362 | 0.170 |
Why?
| | Cells, Cultured | 5 | 2018 | 3885 | 0.170 |
Why?
| | Transsexualism | 1 | 2019 | 17 | 0.160 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 179 | 0.160 |
Why?
| | Glucose Metabolism Disorders | 1 | 2019 | 10 | 0.160 |
Why?
| | Gene Expression | 4 | 2014 | 1421 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 139 | 0.160 |
Why?
| | Off-Label Use | 1 | 2019 | 51 | 0.160 |
Why?
| | Pyridines | 2 | 2013 | 425 | 0.160 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.160 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2018 | 9 | 0.160 |
Why?
| | Pilot Projects | 1 | 2023 | 1373 | 0.160 |
Why?
| | Lamin Type B | 1 | 2018 | 5 | 0.160 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 5 | 0.160 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 225 | 0.150 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 8 | 0.150 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.150 |
Why?
| | Ovariectomy | 5 | 2011 | 116 | 0.150 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 172 | 0.150 |
Why?
| | Germ-Line Mutation | 2 | 2018 | 130 | 0.150 |
Why?
| | Colorectal Neoplasms | 2 | 2023 | 615 | 0.150 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2018 | 26 | 0.150 |
Why?
| | Exercise | 3 | 2018 | 1644 | 0.150 |
Why?
| | Blotting, Northern | 4 | 2000 | 193 | 0.150 |
Why?
| | Hyponatremia | 1 | 2018 | 37 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 193 | 0.150 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 206 | 0.150 |
Why?
| | Zebrafish Proteins | 1 | 2020 | 246 | 0.150 |
Why?
| | Molecular Sequence Data | 8 | 2000 | 2785 | 0.150 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2018 | 67 | 0.150 |
Why?
| | Recovery of Function | 2 | 2020 | 574 | 0.150 |
Why?
| | Protein Kinase C | 3 | 1995 | 273 | 0.140 |
Why?
| | Sleep | 2 | 2020 | 631 | 0.140 |
Why?
| | Resistance Training | 2 | 2018 | 113 | 0.140 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 227 | 0.140 |
Why?
| | Thermogenesis | 1 | 2017 | 37 | 0.140 |
Why?
| | Gene Deletion | 3 | 2011 | 356 | 0.140 |
Why?
| | Gonadotropins | 4 | 2003 | 37 | 0.140 |
Why?
| | Prosencephalon | 3 | 2008 | 45 | 0.140 |
Why?
| | Parathyroid Neoplasms | 3 | 2003 | 11 | 0.140 |
Why?
| | Homeostasis | 2 | 2018 | 573 | 0.140 |
Why?
| | Pituitary-Adrenal System | 1 | 2018 | 130 | 0.140 |
Why?
| | Microarray Analysis | 1 | 2017 | 118 | 0.140 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 993 | 0.140 |
Why?
| | Transgender Persons | 1 | 2019 | 135 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1518 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2018 | 12544 | 0.130 |
Why?
| | Genes, jun | 1 | 1996 | 9 | 0.130 |
Why?
| | Adiposity | 2 | 2018 | 457 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 517 | 0.130 |
Why?
| | Genes, fos | 1 | 1996 | 33 | 0.130 |
Why?
| | Glycoprotein Hormones, alpha Subunit | 3 | 1990 | 22 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 725 | 0.130 |
Why?
| | Binding Sites | 2 | 2015 | 1168 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 245 | 0.130 |
Why?
| | Dopamine | 1 | 2018 | 236 | 0.130 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 101 | 0.130 |
Why?
| | Leuprolide | 1 | 2015 | 19 | 0.130 |
Why?
| | Molecular Conformation | 1 | 2015 | 135 | 0.130 |
Why?
| | Pituitary Gland, Anterior | 4 | 2007 | 39 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 663 | 0.120 |
Why?
| | Histone Deacetylase 6 | 1 | 2015 | 19 | 0.120 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 33 | 0.120 |
Why?
| | Testicular Diseases | 1 | 1995 | 6 | 0.120 |
Why?
| | Cytoprotection | 1 | 2015 | 51 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 1998 | 355 | 0.120 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 35 | 0.120 |
Why?
| | Mutant Proteins | 1 | 2015 | 95 | 0.120 |
Why?
| | Gene Amplification | 1 | 2015 | 95 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 85 | 0.120 |
Why?
| | Adolescent | 6 | 2020 | 17837 | 0.120 |
Why?
| | Societies, Scientific | 1 | 2014 | 47 | 0.120 |
Why?
| | Hypothyroidism | 1 | 1995 | 64 | 0.120 |
Why?
| | Publications | 1 | 2014 | 37 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2019 | 640 | 0.120 |
Why?
| | Gene Silencing | 1 | 2015 | 171 | 0.120 |
Why?
| | Reference Standards | 1 | 2014 | 159 | 0.120 |
Why?
| | Catalytic Domain | 1 | 2015 | 196 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 858 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.110 |
Why?
| | Menopause | 2 | 2007 | 271 | 0.110 |
Why?
| | Tubulin | 1 | 2015 | 123 | 0.110 |
Why?
| | DNA Primers | 3 | 2008 | 510 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 154 | 0.110 |
Why?
| | Cell Hypoxia | 1 | 2015 | 220 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2014 | 154 | 0.110 |
Why?
| | Blotting, Western | 3 | 2002 | 1147 | 0.110 |
Why?
| | Chorionic Gonadotropin | 2 | 2011 | 78 | 0.110 |
Why?
| | Phosphorylation | 2 | 2019 | 1569 | 0.110 |
Why?
| | Indoles | 1 | 2015 | 304 | 0.110 |
Why?
| | Cytoskeleton | 2 | 2007 | 176 | 0.110 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 20 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 698 | 0.110 |
Why?
| | Hepatocyte Growth Factor | 1 | 2013 | 32 | 0.110 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 249 | 0.110 |
Why?
| | Patient Readmission | 1 | 2018 | 610 | 0.110 |
Why?
| | Pedigree | 1 | 2014 | 460 | 0.100 |
Why?
| | Olfactory Pathways | 2 | 2010 | 56 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2013 | 800 | 0.100 |
Why?
| | Professional Practice | 1 | 2013 | 62 | 0.100 |
Why?
| | Aggression | 1 | 2014 | 183 | 0.100 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2018 | 128 | 0.100 |
Why?
| | Testis | 2 | 1990 | 133 | 0.100 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 796 | 0.100 |
Why?
| | Sulfonamides | 1 | 2015 | 445 | 0.100 |
Why?
| | G2 Phase | 1 | 2012 | 31 | 0.100 |
Why?
| | rac GTP-Binding Proteins | 2 | 2002 | 34 | 0.100 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1992 | 81 | 0.100 |
Why?
| | Prospective Studies | 1 | 2023 | 6217 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2013 | 149 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2014 | 339 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 54 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2012 | 45 | 0.100 |
Why?
| | Triptorelin Pamoate | 3 | 1986 | 19 | 0.100 |
Why?
| | CpG Islands | 1 | 2012 | 117 | 0.100 |
Why?
| | Cell Count | 2 | 2011 | 303 | 0.100 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 110 | 0.100 |
Why?
| | Reference Values | 3 | 2010 | 743 | 0.100 |
Why?
| | Rats, Inbred Strains | 7 | 1990 | 362 | 0.100 |
Why?
| | Pituitary Hormones | 2 | 2008 | 16 | 0.100 |
Why?
| | Age Factors | 2 | 2014 | 2894 | 0.100 |
Why?
| | Libido | 2 | 2010 | 24 | 0.100 |
Why?
| | Superovulation | 1 | 2011 | 8 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2353 | 0.090 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2011 | 14 | 0.090 |
Why?
| | Genes, p53 | 1 | 2011 | 61 | 0.090 |
Why?
| | Mutation | 4 | 2021 | 3345 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6345 | 0.090 |
Why?
| | Thyroid Hormones | 2 | 2008 | 53 | 0.090 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2011 | 43 | 0.090 |
Why?
| | Mice, 129 Strain | 1 | 2011 | 75 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 103 | 0.090 |
Why?
| | Feedback, Physiological | 1 | 2011 | 68 | 0.090 |
Why?
| | Pituitary Hormone-Releasing Hormones | 2 | 1990 | 10 | 0.090 |
Why?
| | Integrases | 1 | 2011 | 116 | 0.090 |
Why?
| | Kisspeptins | 2 | 2007 | 5 | 0.090 |
Why?
| | Cautery | 1 | 2010 | 3 | 0.090 |
Why?
| | Amenorrhea | 2 | 2008 | 27 | 0.090 |
Why?
| | Precipitin Tests | 2 | 2002 | 88 | 0.090 |
Why?
| | Placenta | 2 | 1997 | 625 | 0.090 |
Why?
| | Genes, Dominant | 2 | 2020 | 94 | 0.090 |
Why?
| | Pituitary Hormones, Anterior | 2 | 2007 | 4 | 0.090 |
Why?
| | Sphenoid Bone | 1 | 2010 | 15 | 0.090 |
Why?
| | Flavonoids | 2 | 2002 | 66 | 0.090 |
Why?
| | Central Nervous System Cysts | 1 | 2010 | 11 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2015 | 731 | 0.090 |
Why?
| | Cell Division | 1 | 2012 | 758 | 0.090 |
Why?
| | Infertility, Male | 1 | 1990 | 59 | 0.090 |
Why?
| | Follicle Stimulating Hormone, beta Subunit | 5 | 1990 | 28 | 0.090 |
Why?
| | Genes, Retinoblastoma | 2 | 2003 | 8 | 0.080 |
Why?
| | Nucleic Acid Hybridization | 5 | 2003 | 187 | 0.080 |
Why?
| | Hypoxia | 1 | 2015 | 957 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2014 | 685 | 0.080 |
Why?
| | Prognosis | 2 | 2019 | 3327 | 0.080 |
Why?
| | DNA Damage | 1 | 2011 | 351 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 347 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2007 | 194 | 0.080 |
Why?
| | Estrus | 1 | 2008 | 11 | 0.080 |
Why?
| | Cell Adhesion | 2 | 2014 | 431 | 0.080 |
Why?
| | Thyrotropin | 3 | 2007 | 99 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1167 | 0.080 |
Why?
| | Mice, Nude | 2 | 2020 | 630 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 411 | 0.080 |
Why?
| | Cognition | 2 | 2006 | 989 | 0.080 |
Why?
| | Zebrafish | 2 | 2023 | 411 | 0.080 |
Why?
| | Diabetes Complications | 1 | 2010 | 211 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2010 | 243 | 0.070 |
Why?
| | Carcinoma | 2 | 2003 | 198 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 445 | 0.070 |
Why?
| | Prolactin | 2 | 2007 | 96 | 0.070 |
Why?
| | Phenotype | 3 | 2020 | 2796 | 0.070 |
Why?
| | Protein Multimerization | 1 | 2008 | 157 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2002 | 750 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 961 | 0.070 |
Why?
| | Research Design | 1 | 2013 | 928 | 0.070 |
Why?
| | Affect | 2 | 2006 | 246 | 0.070 |
Why?
| | Receptors, Steroid | 1 | 2007 | 47 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 133 | 0.070 |
Why?
| | Orchiectomy | 5 | 1990 | 57 | 0.070 |
Why?
| | Protein Precursors | 1 | 2007 | 119 | 0.070 |
Why?
| | Models, Neurological | 1 | 2008 | 212 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2011 | 1947 | 0.070 |
Why?
| | HIV-1 | 1 | 2012 | 768 | 0.070 |
Why?
| | Ethanol | 1 | 2010 | 538 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 959 | 0.070 |
Why?
| | Age Determination by Skeleton | 1 | 1986 | 16 | 0.070 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 367 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 132 | 0.070 |
Why?
| | Tretinoin | 1 | 2006 | 122 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 3 | 2011 | 3044 | 0.060 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 64 | 0.060 |
Why?
| | Nerve Net | 1 | 2008 | 226 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2015 | 1842 | 0.060 |
Why?
| | Receptors, Estrogen | 2 | 2002 | 372 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2014 | 396 | 0.060 |
Why?
| | Restriction Mapping | 3 | 1995 | 77 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2007 | 337 | 0.060 |
Why?
| | Receptors, LHRH | 1 | 2004 | 14 | 0.060 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 197 | 0.060 |
Why?
| | Time Factors | 5 | 2019 | 6115 | 0.060 |
Why?
| | Neurites | 1 | 2004 | 43 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 923 | 0.060 |
Why?
| | Hyperparathyroidism | 1 | 2003 | 12 | 0.060 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2003 | 16 | 0.060 |
Why?
| | Floxuridine | 1 | 2023 | 5 | 0.060 |
Why?
| | Genes, BRCA2 | 1 | 2003 | 24 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2007 | 931 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2023 | 49 | 0.050 |
Why?
| | DNA Probes | 3 | 1992 | 59 | 0.050 |
Why?
| | Polychlorinated Dibenzodioxins | 1 | 2003 | 5 | 0.050 |
Why?
| | Pentobarbital | 1 | 2003 | 16 | 0.050 |
Why?
| | Discrimination Learning | 1 | 2003 | 47 | 0.050 |
Why?
| | Verbal Learning | 1 | 2003 | 63 | 0.050 |
Why?
| | ras GTPase-Activating Proteins | 1 | 2002 | 13 | 0.050 |
Why?
| | Two-Hybrid System Techniques | 1 | 2002 | 52 | 0.050 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2002 | 66 | 0.050 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2002 | 11 | 0.050 |
Why?
| | rho GTP-Binding Proteins | 1 | 2002 | 61 | 0.050 |
Why?
| | COS Cells | 1 | 2002 | 175 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2003 | 134 | 0.050 |
Why?
| | Genes, Reporter | 1 | 2002 | 257 | 0.050 |
Why?
| | Reading | 1 | 2003 | 149 | 0.050 |
Why?
| | Mental Recall | 1 | 2003 | 171 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2002 | 69 | 0.050 |
Why?
| | Aurora Kinase B | 1 | 2021 | 7 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2003 | 110 | 0.050 |
Why?
| | Estrogen Receptor alpha | 1 | 2002 | 121 | 0.050 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 52 | 0.050 |
Why?
| | MEF2 Transcription Factors | 1 | 2000 | 55 | 0.050 |
Why?
| | Receptors, Glucocorticoid | 1 | 2002 | 130 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2002 | 157 | 0.040 |
Why?
| | Protein Transport | 1 | 2002 | 395 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2018 | 9087 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2020 | 42 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 355 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 316 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2000 | 286 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 318 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 81 | 0.040 |
Why?
| | beta Catenin | 1 | 2002 | 219 | 0.040 |
Why?
| | Ligands | 1 | 2002 | 561 | 0.040 |
Why?
| | Body Height | 2 | 1995 | 180 | 0.040 |
Why?
| | Indolizines | 1 | 2019 | 3 | 0.040 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 5 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 345 | 0.040 |
Why?
| | Attention | 1 | 2003 | 393 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 84 | 0.040 |
Why?
| | Progesterone | 2 | 2019 | 232 | 0.040 |
Why?
| | Minority Groups | 1 | 2021 | 227 | 0.040 |
Why?
| | Quinoxalines | 1 | 2019 | 60 | 0.040 |
Why?
| | Penile Erection | 1 | 1999 | 6 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 111 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 36 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 1999 | 72 | 0.040 |
Why?
| | Actigraphy | 1 | 2019 | 74 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 108 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 151 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2002 | 384 | 0.040 |
Why?
| | Gender Identity | 1 | 2019 | 102 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 385 | 0.040 |
Why?
| | Kinetics | 3 | 1992 | 1551 | 0.040 |
Why?
| | Androstadienes | 1 | 1999 | 97 | 0.040 |
Why?
| | Sequence Homology | 1 | 1998 | 39 | 0.040 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2018 | 7 | 0.040 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| | Sequence Homology, Nucleic Acid | 2 | 1996 | 152 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2021 | 228 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 47 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 322 | 0.040 |
Why?
| | Cortisone | 1 | 2018 | 8 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 410 | 0.040 |
Why?
| | Absorptiometry, Photon | 1 | 2019 | 224 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 233 | 0.040 |
Why?
| | Hip Joint | 1 | 2019 | 126 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2019 | 177 | 0.040 |
Why?
| | Disease | 1 | 1999 | 85 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1998 | 256 | 0.040 |
Why?
| | Leadership | 1 | 2021 | 292 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 308 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.040 |
Why?
| | HIV Infections | 1 | 2012 | 2469 | 0.040 |
Why?
| | Sirolimus | 1 | 1999 | 181 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 289 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2000 | 395 | 0.040 |
Why?
| | Octamer Transcription Factor-6 | 1 | 1997 | 1 | 0.040 |
Why?
| | Vitamin D | 1 | 2020 | 341 | 0.040 |
Why?
| | Cell Communication | 1 | 1999 | 279 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1143 | 0.030 |
Why?
| | Pregnancy | 1 | 2008 | 5517 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 635 | 0.030 |
Why?
| | DNA Footprinting | 1 | 1996 | 28 | 0.030 |
Why?
| | Culture Techniques | 1 | 1996 | 78 | 0.030 |
Why?
| | Aging | 1 | 2006 | 1618 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 797 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1997 | 167 | 0.030 |
Why?
| | Spodoptera | 1 | 1996 | 36 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2018 | 267 | 0.030 |
Why?
| | Leucine Zippers | 1 | 1996 | 16 | 0.030 |
Why?
| | Consensus Sequence | 1 | 1996 | 70 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 591 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 317 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 474 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 522 | 0.030 |
Why?
| | Sequence Alignment | 1 | 1996 | 323 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 594 | 0.030 |
Why?
| | Brain | 2 | 2000 | 2371 | 0.030 |
Why?
| | Transcription Factor AP-1 | 1 | 1996 | 80 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 142 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 723 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 440 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 696 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 1996 | 151 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 4622 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 1999 | 646 | 0.030 |
Why?
| | Neuropeptides | 1 | 1995 | 65 | 0.030 |
Why?
| | Adrenal Glands | 2 | 1992 | 66 | 0.030 |
Why?
| | E-Selectin | 1 | 2014 | 53 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2014 | 89 | 0.030 |
Why?
| | Dactinomycin | 1 | 1994 | 25 | 0.030 |
Why?
| | Half-Life | 1 | 1994 | 141 | 0.030 |
Why?
| | Loss of Heterozygosity | 2 | 2003 | 40 | 0.030 |
Why?
| | Staurosporine | 1 | 1992 | 21 | 0.030 |
Why?
| | Alkaloids | 1 | 1992 | 22 | 0.030 |
Why?
| | Gonads | 1 | 1992 | 21 | 0.030 |
Why?
| | Feedback | 2 | 1990 | 144 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 433 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 951 | 0.030 |
Why?
| | Depression, Chemical | 1 | 1992 | 22 | 0.030 |
Why?
| | Choriocarcinoma | 1 | 1992 | 8 | 0.030 |
Why?
| | RNA | 1 | 1998 | 809 | 0.030 |
Why?
| | DNA Mutational Analysis | 2 | 2003 | 372 | 0.030 |
Why?
| | Serum Albumin | 1 | 2013 | 137 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2012 | 35 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 531 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 1958 | 0.020 |
Why?
| | Cohort Studies | 2 | 2013 | 4895 | 0.020 |
Why?
| | Mortality | 1 | 2013 | 287 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 14 | 0.020 |
Why?
| | Uterine Neoplasms | 1 | 1992 | 73 | 0.020 |
Why?
| | Mitotic Index | 1 | 2011 | 26 | 0.020 |
Why?
| | Puberty | 1 | 1992 | 135 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1467 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 39 | 0.020 |
Why?
| | Organ Specificity | 1 | 1992 | 268 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2013 | 304 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 385 | 0.020 |
Why?
| | Radiography | 2 | 2011 | 812 | 0.020 |
Why?
| | Risk | 1 | 2013 | 812 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 219 | 0.020 |
Why?
| | Psychomotor Performance | 2 | 2004 | 280 | 0.020 |
Why?
| | Ovarian Diseases | 1 | 1990 | 12 | 0.020 |
Why?
| | Enzyme Activation | 1 | 1992 | 785 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 641 | 0.020 |
Why?
| | Tumor Burden | 1 | 2011 | 259 | 0.020 |
Why?
| | Ejaculation | 1 | 1990 | 11 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4407 | 0.020 |
Why?
| | Vaginismus | 1 | 2010 | 1 | 0.020 |
Why?
| | Norpregnenes | 1 | 2010 | 3 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2010 | 17 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 316 | 0.020 |
Why?
| | Dyspareunia | 1 | 2010 | 8 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 523 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 1990 | 134 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 616 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1139 | 0.020 |
Why?
| | Psychology | 1 | 2010 | 82 | 0.020 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 32 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 2 | 1986 | 45 | 0.020 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 1988 | 14 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 230 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 206 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 222 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1990 | 385 | 0.020 |
Why?
| | Receptors, Kisspeptin-1 | 1 | 2007 | 2 | 0.020 |
Why?
| | Netrin-1 | 1 | 2007 | 11 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2128 | 0.020 |
Why?
| | Child | 6 | 2010 | 18407 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 607 | 0.020 |
Why?
| | Chemokines, CXC | 1 | 2007 | 60 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2007 | 74 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 71 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 78 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2009 | 349 | 0.020 |
Why?
| | Databases, Factual | 1 | 2010 | 1125 | 0.020 |
Why?
| | Barium Sulfate | 1 | 1985 | 15 | 0.020 |
Why?
| | Food, Formulated | 1 | 1985 | 14 | 0.020 |
Why?
| | Intestinal Polyps | 1 | 1985 | 15 | 0.020 |
Why?
| | Leydig Cells | 1 | 1985 | 11 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1988 | 666 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1985 | 121 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2478 | 0.010 |
Why?
| | Jaw Neoplasms | 1 | 2003 | 2 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 1985 | 215 | 0.010 |
Why?
| | Signal Detection, Psychological | 1 | 2003 | 21 | 0.010 |
Why?
| | Mifepristone | 1 | 2003 | 60 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2003 | 33 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 2003 | 162 | 0.010 |
Why?
| | Ultrasonography | 1 | 1986 | 633 | 0.010 |
Why?
| | Syndrome | 1 | 2003 | 333 | 0.010 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2003 | 39 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2537 | 0.010 |
Why?
| | Reaction Time | 1 | 2003 | 376 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2003 | 440 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1226 | 0.010 |
Why?
| | Administration, Oral | 1 | 2003 | 728 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2003 | 225 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2013 | 2177 | 0.010 |
Why?
| | Hospitalization | 1 | 2009 | 1750 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2003 | 2218 | 0.010 |
Why?
| | Growth Hormone | 2 | 1989 | 103 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1986 | 4411 | 0.010 |
Why?
| | Decision Making | 1 | 2003 | 782 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1990 | 1982 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1994 | 65 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 1994 | 52 | 0.010 |
Why?
| | Alleles | 1 | 1994 | 789 | 0.010 |
Why?
| | Child, Preschool | 3 | 1992 | 9111 | 0.010 |
Why?
| | Follicular Phase | 1 | 1990 | 36 | 0.010 |
Why?
| | Ovulation Induction | 1 | 1990 | 49 | 0.010 |
Why?
| | Densitometry | 1 | 1990 | 29 | 0.010 |
Why?
| | Propylthiouracil | 1 | 1989 | 2 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1989 | 68 | 0.010 |
Why?
| | Triiodothyronine | 1 | 1989 | 42 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1989 | 173 | 0.000 |
Why?
| | Molecular Structure | 1 | 1990 | 434 | 0.000 |
Why?
| | Introns | 1 | 1989 | 227 | 0.000 |
Why?
| | Exons | 1 | 1989 | 302 | 0.000 |
Why?
| | RNA Probes | 1 | 1987 | 13 | 0.000 |
Why?
| | Affinity Labels | 1 | 1987 | 25 | 0.000 |
Why?
| | Biotin | 1 | 1987 | 20 | 0.000 |
Why?
| | Azides | 1 | 1987 | 46 | 0.000 |
Why?
| | Ovarian Cysts | 1 | 1986 | 8 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 921 | 0.000 |
Why?
| | Hypothalamic Neoplasms | 1 | 1986 | 9 | 0.000 |
Why?
| | Hamartoma | 1 | 1986 | 20 | 0.000 |
Why?
| | Bone Development | 1 | 1986 | 47 | 0.000 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 1986 | 28 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1986 | 198 | 0.000 |
Why?
| | Enema | 1 | 1985 | 38 | 0.000 |
Why?
| | Uterus | 1 | 1986 | 192 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1986 | 286 | 0.000 |
Why?
| | Energy Intake | 1 | 1985 | 427 | 0.000 |
Why?
|
|
Wierman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|